Takeda Pharmaceutical Co Ltd (NYSE:TAK) Shares Sold by Wheatland Advisors Inc.

Share on StockTwits

Wheatland Advisors Inc. lessened its stake in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 3.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,928 shares of the company’s stock after selling 663 shares during the quarter. Wheatland Advisors Inc.’s holdings in Takeda Pharmaceutical were worth $300,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of TAK. Adelphi Capital LLP acquired a new position in shares of Takeda Pharmaceutical during the first quarter worth about $188,841,000. FMR LLC increased its position in shares of Takeda Pharmaceutical by 9,453,973.8% during the first quarter. FMR LLC now owns 7,563,259 shares of the company’s stock worth $154,063,000 after acquiring an additional 7,563,179 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Takeda Pharmaceutical during the first quarter worth about $60,381,000. First Trust Advisors LP purchased a new stake in shares of Takeda Pharmaceutical during the first quarter worth about $53,436,000. Finally, Parametric Portfolio Associates LLC increased its position in shares of Takeda Pharmaceutical by 114.9% during the first quarter. Parametric Portfolio Associates LLC now owns 3,312,996 shares of the company’s stock worth $67,486,000 after acquiring an additional 1,771,039 shares during the last quarter. Institutional investors own 10.83% of the company’s stock.

Shares of NYSE TAK traded down $0.14 during midday trading on Friday, reaching $16.46. 1,714,813 shares of the company’s stock were exchanged, compared to its average volume of 1,553,733. Takeda Pharmaceutical Co Ltd has a 52-week low of $15.50 and a 52-week high of $21.95. The company has a market capitalization of $25.94 billion, a PE ratio of 32.27 and a beta of 0.69. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 1.01. The stock’s fifty day moving average price is $17.38.

A number of analysts have recently issued reports on TAK shares. Daiwa Capital Markets lowered Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a research report on Thursday, August 15th. Zacks Investment Research lowered Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, ValuEngine lowered Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Recommended Story: What are different types of coverage ratios?

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Expect Comerica Incorporated  Will Announce Quarterly Sales of $839.87 Million
Brokerages Expect Comerica Incorporated Will Announce Quarterly Sales of $839.87 Million
$2.44 Billion in Sales Expected for Newell Brands Inc  This Quarter
$2.44 Billion in Sales Expected for Newell Brands Inc This Quarter
WP Carey  Downgraded by Zacks Investment Research
WP Carey Downgraded by Zacks Investment Research
Tortoise Capital Advisors L.L.C. Grows Stake in Delek Logistics Partners LP
Tortoise Capital Advisors L.L.C. Grows Stake in Delek Logistics Partners LP
Cheniere Energy Partners LP  Shares Bought by Tortoise Capital Advisors L.L.C.
Cheniere Energy Partners LP Shares Bought by Tortoise Capital Advisors L.L.C.
Tortoise Capital Advisors L.L.C. Has $126.54 Million Stock Holdings in Equitrans Midstream
Tortoise Capital Advisors L.L.C. Has $126.54 Million Stock Holdings in Equitrans Midstream


 
© 2006-2019 Zolmax.